Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Dyne Therapeutics (DYN) to $11 from $13 and keeps a Perform rating on the shares following quarterly results and business update. The firm continues to see upcoming Phase 1/2 DELIVER expansion cohort data for DYNE-251/DMD in December 2025 as an important clearing event, supporting a potential BLA submission for accelerated approval in Q2 2026. In October, Novartis (NVS) announced the acquisition of competitor Avidity. While the deal broadly provided positive readthrough to antisense oligonucleotides for rare diseases, the firm sees the deal reinforcing its thesis that Dyne’s programs require further derisking on safety before assigning additional value.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $38 from $41 at Evercore ISI
- Dyne Therapeutics price target raised to $46 from $38 at H.C. Wainwright
- Positive Outlook for Dyne Therapeutics: Strong Financial Performance and Promising Clinical Developments Support Buy Rating
- Dyne Therapeutics Advances in Neuromuscular Disease Therapies
- Dyne Therapeutics reports Q3 EPS (76c), consensus (85c)